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Abstract. Mice immunized against DS5-hCG-β and DS6-hCG-β, chemical analogs of β- 
subunit of human choriogonadotropin (hCG-β) in which 5 and 6 disulphide bonds 
respectively were reduced and alkylated, were found to produce antibodies specific to hCG 
without significant crossreactivity with human lutropin (hLH) as tested in a 
radioimmunoassay. In contrast, mice immunized against the native hCG-β subunit produced 
hLH crossreacting antibodies. While the anti-DS5, DS6-hCG-β serum was capable of 
selectively blocking the binding of [125I]-hCG to rat testicular LH/hCG receptors, it failed to 
inhibit the binding of [125I]-hLH to the same receptors. The radioimmunoassay for hCG using 
the mouse anti-DS5, DS6-hCG-β serum was not as sensitive as that employing rabbit anti- 
DS5, DS6-hCG-β serum. The minimal detection limit was 5 ng/ml for the mouse antibody as
compared to 1 ng/ml for the rabbit antibody. 
 
Keywords. hcG Specific antibody; disulphide modified hCG-β-subunit; immuno-
contraceptive. 
 
Introduction 
 
Although antibodies to human choriogonadotropin β-subunit (hCG-β) can
discriminate between hCG and human lutropin (hLH), they lack absolute
specificity. The degree of hLH crossreactivity of the antibody varies with the 
preparation of hCG-β, ranging from 10 to 30%. Nevertheless, antibody to hCG-β 
is considerably more specific than antibody to hCG and this specificity is most 
likely due to the differences in the physicochemical characteristics of hLH and
hCG-β (Bhal, 1980). hCG-β not only has an additional 30-amino acid residue 
sequence at its carboxy-terminus but also has certain other domains in the 
polypeptide chain with variable sequences. Furthermore hCG-β undergoes a
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conformational change when it is dissociated from hCG-α (Hilgenfeldt et al., 
1974). The antigenic determinants being conformational in nature, this change in 
the conformation results in the loss of hLH crossreactivity of the sites. We have 
attempted to modify intact hCG-β in order to enhance its specificity as an antigen 
rather than use the unique carboxyterminal peptide which is a weak antigen 
(Matsuura et al., 1979). Earlier work from our laboratory has demonstrated that 
progressive reduction and alkylation of disulphide linkages in hCG-β results in 
loss of antigenic determinants common to hCG and hLH (Bahl et al., 1976). 
Among the various derivatives, reduced and S-alkylated hCG-β in which 5- 
disulphide bonds were modified (DS5-hCG-β) retained only determinants unique 
to hCG with complete loss of those crossreacting with hLH antibodies (Ghai et al., 
1980). Immunization of rabbits with DS5-hCG-β prepared according to the 
methods standardized in our laboratory yielded antibodies specific to hCG by 
immunological and biological criteria (Pandian et al., 1980). With the idea that this 
chemical derivative of hCG-β would be useful as a means of immunological 
control of fertility in humans, studies were initiated to test the immunogenic 
specificity of the antigen in other animals. We report here that a sequential 
injection of DS5-hCG-β and DS6-hCG-β, a fully reduced and alkylated derivative 
of hCG-β, into mice resulted in antibodies specific to hCG. As a control, another 
group of mice was immunized against native hCG-β. This group of mice produced 
antibodies to hCG which were crossreactive with hLH to a significant extent.
 
Materials and methods 
 
Sephadex-G-25 (coarse), G-100, Sepharose-4B and diethylaminoethyl (DEAE)
Sephadex A-50 were obtained from Pharmacia Fine Chemicals, Piscataway, New 
Jersey, USA. Freund’s complete adjuvant was a product of Gibco, Grand Island,
New York, USA. Carrier free Na125I was purchased from Amersham Corp.,
Arlington, Illinois, USA. Bovine-ү-globulin, bovine serum albumin and 
glutaraldehyde (25% solution) were purchased from Sigma Chemical Company,
St. Louis, Missouri, USA. All other chemicals were of certified Analytical grade.
BALB/C mice were used in this study. 
 
Preparation of DS5-hCG-β and DS6-hCG-β 
 
 
The β-subunit of hCG was prepared by dissociation of hCG in 8M urea and
chromatography over DEAE-Sephadex-A 50 (Swaminathan and Bahl, 1975). To
remove the last traces of hCG, the β-subunitwas treated with an immunoadsorbent
prepared by coupling antibodies to hCG-α to CNBr-activated Sepharose (Pandian
et al., 1980). After determining the binding capacity of the immunoadsorbent
hCG-β was treated with a calculated amount of the immunoadsorbent. Details of 
the procedure are given elsewhere (Pandian et al., 1980). The anti hCG-α 
immunoadsorbent treated hCG-β was then partially or completely reduced and
alkylated to prepare DS5-hCG-β and DS6-hCG-β respectively (Ghal et al., 1980).
Amino acid analysis for carboxymethylcysteine residues was later carried out to
confirm the degree of reduction. The hLH cross-reactivity of the preparation was
monitored by radioimmunoassay of DS5-hCG-β in a [125I]-hLH-anti-hLH radio
immunoassay (RIA) system. In order to ensure the complete removal of hLH
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crossreactivity of the antigen, it was treated with a calculated amount of an
immunoadsorbent, prepared by coupling antibodies to hLH to CNBr-activated
Sepharose. The efficacy of the treatment was monitored by a homologous hLH 
RIA. This material was then conjugated to Keyhole limpet hemocyanin in a 1:1
ratio (w/w) using glutaraldehyde as the bifunctional cross-linking reagent
(Pandian et al., 1980). The resulting conjugate, DS5-hCG-β -hem and DS6-hCG-β 
were used to immunize mice. 
 
Immunization of mice and collection of blood samples 
 
Mice were immunized by intraperitoneal injection. A water in oil emulsion was 
prepared by mixing equal volumes of a saline solution of the immunogen [hCG-β 
or DS5-hCG-β coupled with hemocyanin (DS5-hCG-β-hem) or DS6-hCG-β] and 
Freund’s complete adjuvant. Mice received two injections of DS5-hCG-β-hem 
(250 µg/mouse) one month apart. Twenty day after the second injection they 
received DS6-hCG-β (100 µg/mouse). A second group of mice was immunized
similarly by these injections of native hCG-β-subunit (100 µg/mouse). Blood
samples were collected by occular puncture. Serum was later separated and frozen
with 0.01% sodium azide as a preservative. 
 
Titer of antisera 
 
Serum (200 µl) at various dilutions (1:10 to 1:10,000) was incubated with [125I]- 
hCG for 1 hat 37°C followed by the addition of 10 µl of 10% ammonium acetate in
ethanol. The tubes were kept for 1 h at 4°C, then centrifuged, supernatants 
decanted, residual liquid removed by wiping with filter paper strips and finally the 
pellets were counted for antibody bound readioactivity. The dilution of the 
antiserum binding 20% of the [125I]-hCG (40-50 µCi/µg) was chosen for 
radioimmunoassay. 
 
Radioiodination and radioimmunoassay 
 
 
The radioiodination of highly purified hCG for RIA was performed essentially by 
the chloramine-T procedure of Greenwood et al. (1963) with minor 
modifications. 
 
The radioimmunoassay was performed essentially as per the procedure of
Bellisario and Bahl (1975) . The results were expressed as B/B0×100 and plotted
against log dose of hCG standards. B0 represents cpm radioactivity bound in the
absence of any competing antigen and Β represents cpm radioactivity bound in the
presence of various levels of competing standard hCG or unknown sample. The
radioimmunoassay data were also analyzed by a computer, Wang Model 2200,
using program RIADS-2200, based on the method developed by Rodbard and
Lewald (1970). 
 
Radioimmuno-receptor assay 
 
Rat testicular homogenate was used as a source of hCG/hLH receptors. Testes 
were removed from a healthy adult rat and placed on ice. After decapsulating the 
pair of testes was homogenized in 20 ml of 0.05 Μ Tris-HCl buffer pH 7.2 
containing 1mM CaCl2 (TCbuffer) in a motorized Potter-Elvehjem tissue grinder 
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(no more than 6 strokes). The homogenate was centrifuged at 1,000 g for 15 min in
a Sorvall-RC 2B refrigerated centrifuge. The pellet was resuspended in 40 ml of
TC buffer containing 0.2% BSA. Antisera (200 µl) serially diluted or standards 
were incubated with 0.5 ml aliquots of the testicular homogenate and 100,000 cpm
of [125I]-hCG or [125I]-hLH for 1 h at 37°C in a Dubnoff metabolic shaker. At the 
end of the incubation, the tubes were centrifuged at 4°C at 2000 g for 15 min, the 
supernatants decanted, the pellets washed with 2.5 ml of chilled TC buffer by
resuspension and centrifuged at 2000 g for 15 min. The supernatants were
decanted, and the liquid adhering to the walls wiped with filter paper strips. The
pellets were counted for receptor bound radioactivity. Results were expressed as 
B/B0×100 vs log dose of Standard hormone or dilution of antiserum. B0 represents 
radioactivity (cpm) bound to receptors in the absence of competing standard 
hormone or antiserum and Β represents radioactivity bound to the receptors in the 
presence of standard hormone or antiserum. Nonspecific binding was determined
by obtaining cpm bound in the presence of excess of the cold hormone (hCG or 
hLH). 
 
Results and discussion 
 
The antigen 
 
The hCG-β subunit prepared by dissociation of highly purified hCG with urea had 
0.5% contamination as found by the radioreceptor assay. When treated with an 
immunoadsorbent of anti hCG-α antibodies, the contamination (hCG) was 
completely removed (Pandian et al., 1980). This hCG-β was then reduced 
partially under controlled conditions and alkylated to yield DS5-hCG-β On 
analysis, a value of 10.4 was obtained for carboxymethylcysteine residues 
pointing to the reduction on an average of 5.2 disulphide bridges (Ghai et al., 
1980). The material was tested in [125I]-hLH-and-hLH RIA system to monitor the 
presence of hLH-cross reacting material. This amounted approximately to 0.2- 
0.3% (figure 1) of hLH activity. However, after treatment with an
 
 
 
Figure 1. Radioimmunoassay of DS5-hCG-β in the 125I-hLH-anti-hLH system. Human
LH (?)and DS5-hCG-(O) were separately used as standards in an RIA using 125I-hLH and 
anti-hLH serum (1:30,000 dilution of antiserum). For details of the assay, see the text. Results 
are expressed as B/B0×100 vs log dose of the competing antigen. The value of B0 ranged from 
9,000-10,000 cpm corresponding to 27% to 30% specific binding.
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immunoadsorbent of anti-hLH-Sepharose, the crossreactivity was reduced to
negligible level (0.01 % hLH activity). DS5-hCG-β conjugated to Keyhole limpet
hemocyanin was then dialyzed and lyophilized to yield DS5-hCG-β-hem. DS6- 
hCG-β was prepared by complete reduction and alkylation of hCG-β. Amino acid 
analysis gave an average value of 11.96 for the number of CMC residues indicating
that 5.98 disulphide bridges had been reduced and alkylated (Ghai et al., 1980).
 
The antisera
 
Mice were immunized against native hCG-β or DS5-hCG-β-hem as described 
under Methods. The serum levels of antibody after the second injection are
shown in Figure 2. The anti-DS5-hCG-β-hem serum showed very minimal
 
 
 
Figure 2. Titer and crossreactivity of anti-hCG-β serum and anti DS5-hCG-β serum from 
mice immunized against the respective antigens. Data from a representative mouse is given 
here for each antigen. For details of procedure see the text. Results are expressed as B/T × 100 
vs log dilution of antiserum where Β represents cpm bound to the antibody and Τ is the total 
cpm added to the incubation.(?) Binding of 125I-hCG to anti-hCG-β serum; (?) Binding of 
125I-hLH to anti-hCG-β serum; (O) Binding of 125I-hCG to anti-DS5-hCG-β serum; (Δ) 
Binding of 125I-hLH to anti-DS5-hCG-β serum. 
 
 
binding to [125I]-hLH. However, after receiving the third injection (with DS6- 
hCG-β), the antibody level against hCG was elevated with negligible binding to
[125I]-hLH (figure 3). In comparison, the serum from mice immunized against
 
 
 
Figure 3. Titer and crossreactivity of anti-hCG-β serum and anti-DS5, DS6-hCG-β serum 
from mice immunized against the respective antigens. Data from one representative mouse is
given here for each antigen. For details of procedure see the text. Results are expressed as B/
T × 100 dilution of the antiserum. For explanaton, see the legend to figure 2.
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native hCG-β, bound [125I]-hLH to an appreciable extent. When tested in an RIA 
using 1:100 dilution, hLH did not interfere to any appreciable degree when anti- 
DS5-hCG-β serum was used (figure 4). In the case of anti-hCG-β serum, however, 
hLH inhibited the binding of [125I]-hCG to a significant degree (from 40 ng/ml and 
 
 
Figure 4. Radioimmunoassay of hCG and hLH using 1:100 dilution of mouse anti-hCG-β 
(Ο) and anti-DS5-, DS6-hCG-β sera (?). For details of the assay see the text. Results are
expressed as Β/B0×100 vs log dose of the competing antigen where Β represents cpm bound to 
the antiserum in the presence of graded doses of the competing antigen and B0 represents 
cpm bound to the antiserum in the absence of any competing antigen. The value for B0 was 
8000 cpm representing 20% specific binding. 
 
higher). The sensitivity (minimal detection limit) of the assay using mouse anti-
DS5, DS6-hCG-β-hem serum was 5 ng/ml. This, however, was lower than that of
the rabbit antibody based RIA which could measure 1 ng/ml with confidence (K. 
Muralidhar, G. Chaudhuri, J. Lippes and O. P. Bahl–unpublished data). This
confirms and extends our earlier report that the rabbit antibody to DS5, DS6-hCG-
 
 
Figure 5. Radioreceptor assay of hCG in the presence of antibodies to DS5, DS6-hCG-β 
from rabbits (O) and mice (?). Rat testicular homogenate (0.5 ml) was incubated with [125I]- 
hCG and serial dilutions of rabbit or mouse anti-DS5, DS6-hCG-β serum. At the  end of the  
incubation, the receptor bound radioactivity was determined. For details see the text. Resuls
are expressed as B/B0×100 where Β and B0 represent cpm bound in the presence or absence 
of various dilutions of either rabbit or mouse antibody. The value for B0 was 10,000 cpm 
representing 13% specific binding to receptors.
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β was specific to hCG with little or no crossreaction with hLH (Pandian et al.,
1980). In order to ascertain whether the mouse anti-DS5, DS6-hCG-β serum was
capable of selective neutralization of biological activity of hCG, the radio-receptor 
assay was carried out. As shown in figures 5 and 6 the mouse antibody was capable
 
 
 
Figure 6. Radioreceptor assay of [125I]-hLH in the presence of antibodies to DS5, DS6- 
hCG-β from mice. Rat testicular homogenate (0.5 ml) was incubated with [125I]-hLH and
serial dilutions of mouse anti-DS5, DS6-hCG-β serum (O) or standard hLH (?) in amounts
indicated in the figure. At the end of the incubation, the receptor bound radioactivity was 
determined. For details see the text. Results are expressed as B/Bo×100 where Bo represents 
cpm bound in the absence of any competing LH or antibody and Β represents cpm bound in 
the presence of various dilutions of the antibody or standard hLH. The value for Bo was 9000 
cpm representing 10% specific binding to receptors.
 
of blocking the binding of [125I]-hCG to testicular receptors. For comparison, the
effect of rabbit antibody on the binding of [125I]-hCG to receptors is also depicted
in figure 5. In contrast, the binding of [125I]-hLH to testicular receptors was
unaffected by the presence of mouse anti-DS5, DS6-hCG-β serum (figure 6). This 
again demonstrates and confirms the biological specificity of the antibody.
 
A number of placental antigens have been proposed as immuno-contraceptive 
agents (Bhal and Muralidhar, 1980). Among these only hCG has been investigated 
in great detail. Active immunization studies in subhuman primates involving hCG- 
β have demonstrated the possibility of interrupting pregnancy with this immuno- 
gen (Hearn, 1979). These studies have, at the same time, indicated the existence of 
hLH crossreactivity in the anti-hCG-β antibodies. The degree of crossreactivity 
with hLH, however, varied from animal to animal. As the ideal placental immuno- 
contraceptive agent is envisaged as one eliciting antibodies specific to itself without 
cross reactivity with any non-placental tissue antigen including pituitary LH, there 
is a need to improve the specificity of hCG-β antibodies. Although the unique
carboxy terminal peptide of hCG-β produces antibodies to hCG, some of which 
are capable of neutralizing the biological activity of hCG-β an action through 
which it is hoped to terminate pregnancy, they are not specific. Hence, an 
alternative approach, presented here and elsewhere (Pandian et al., 1980) to use 
chemical derivatives of hCG-β was investigated. These studies revealed that
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among the derivatives of hCG-β, DS5-hCG-β and DS6-hCG-β were least
crossreactive with anti-hLH sera (Ghai et al., 1980). It has been shown here that 
mice generate antibodies specific to hCG when they are immunized against 
DS5-hCG-and DS6-hCG-β Although in a direct binding assay, the antibodies 
displayed binding to [125I]-hLH, the binding was of low affinity as compared with 
the binding to [125I]-hCG. This was evident from the fact that in a competitive test 
system such as RIA or RRA, the antibody did not show any binding to hLH. In 
contrast, the antibodies to hCG-β bound [125I]-hLH in a direct binding assay and 
this binding apparently was of considerable affinity as even in an RIA the antibody 
binding to [125I]-hCG was inhibited by the unlabeled hLH. 
 
The immunological and biological specificity of the anti DS5, DS6-hCG-β sera 
in both rabbits (Pandian et al., 1980) and mice points to the possible use of DS5, 
DS6-hCG-β as an immunocontraceptive agent. The lymphocytes from these mice
immunized against DS5-hCG-β and DS6-hCG-β have been used to develop
monoclonal antibodies to hCG without any cross reaction with hLH (Muralidhar 
et al., 1981). The biological effects of active immunization with DS5-hCG-β and
DS6-hCG-β are presently being investigated in a number of laboratory animals
including subhuman primates. 
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